1. Home
  2. GPRO vs TLSA Comparison

GPRO vs TLSA Comparison

Compare GPRO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoPro Inc.

GPRO

GoPro Inc.

HOLD

Current Price

$0.76

Market Cap

154.6M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.22

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRO
TLSA
Founded
2004
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.6M
155.3M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
GPRO
TLSA
Price
$0.76
$1.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.7M
193.3K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
79.08
N/A
EPS
N/A
N/A
Revenue
$651,542,000.00
N/A
Revenue This Year
$23.14
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$1.04
52 Week High
$3.05
$2.60

Technical Indicators

Market Signals
Indicator
GPRO
TLSA
Relative Strength Index (RSI) 40.60 48.02
Support Level $0.69 $1.14
Resistance Level $0.85 $1.44
Average True Range (ATR) 0.06 0.09
MACD 0.01 0.01
Stochastic Oscillator 44.24 52.15

Price Performance

Historical Comparison
GPRO
TLSA

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: